AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MAUI, HAWAII -- SMART, the new teratogenicity management program for Accutane, does not go far enough because too many of the provisions are voluntary, Dr. Kenneth L. Jones said at the annual Hawaii dermatology seminar sponsored by the Skin Disease Education Foundation.
"I think there are many positive aspects to the SMART (System to Manage Accutane-Related Teratogenicity) program, but I think it has not gone far enough," said Dr. Jones, a professor of pediatrics at the University of California, San Diego, and a member of the Teratology Society, which has argued for greater restrictions on Accutane.
Many pregnancies continue to occur in women on Accutane, and many of these exposures are not reported, either to the Food and Drug Administration's MedWatch program or to the Slone Epidemiologic Survey maintained by the Boston University School of Public Health. These exposures need to be recorded in order to know how many there truly are because the results can be so devastating, he said.
Dr. Jones said that he sees many ...